Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Enriched Hematopoetic Stem Cell Infusion · 1 trial · 1 indication
Tests are done at key time points to monitor for donor chimerism by evaluating presence of bone marrow-derived hematopoietic stem cells.
| Arm | Type | Description |
|---|---|---|
| Sickle Cell Disease | EXPERIMENTAL | Recipients treated with an enriched hematopoetic stem cell infusion |
| Non-Malignant Disorders | EXPERIMENTAL | Recipients treated with an enriched hematopoetic stem cell infusion |
| Aplastic Anemia | EXPERIMENTAL | Recipients treated with an enriched hematopoetic stem cell infusion |
| Sickle Cell Disease : Extended Protocol | EXPERIMENTAL | Recipients treated with an enriched hematopoetic stem cell infusion and Campath 1H conditioning |
| Name | Type | Description |
|---|---|---|
| Enriched Hematopoetic Stem Cell Infusion | BIOLOGICAL | Enriched Hematopoetic Stem Cell Infusion |
Inclusion Criteria: The following criteria are established to identify subjects with sickle cell disease (SCD) who have a high predicted morbidity and are at risk for early mortality. Subjects with S/S disease, S/C disease, Hemoglobin H disease, Alpha Thalassemia Major, Thalassemia Major (also know...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Etavopivat Low dose |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE3 | Crizanlizumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE3 | PCV21, 20vPCV |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | CTX001 |
| Agios Pharmaceuticals, Inc. | AGIO | 2 | PHASE2 | Mitapivat |
| Pfizer Inc. | PFE | 1 | PHASE2 | Osivelotor |
| Bristol-Myers Squibb Company | BMY | 1 | PHASE1 | BMS-986470, Famotidine, Pantoprazole |
| Fulcrum Therapeutics, Inc. | FULC | 1 | PHASE2 | Pociredir |
| Beam Therapeutics, Inc. | BEAM | 2 | PHASE1 | BEAM-101 |
| Editas Medicine, Inc. | EDIT | 2 | PHASE1 | EDIT-301 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-3405 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
Enriched Hematopoetic Stem Cell Infusion is an investigational therapy being studied for Sickle Cell Disease. It is a monoclonal antibody-based approach that involves infusing enriched hematopoietic stem cells. The therapy is currently in Phase 1 clinical development, with one completed trial that enrolled 9 participants.
Enriched Hematopoetic Stem Cell Infusion is a monoclonal antibody therapy, but its specific molecular target has not been disclosed. The therapy is being investigated for its potential to treat Sickle Cell Disease by infusing enriched hematopoietic stem cells, though the exact mechanism of action is not publicly detailed.
Enriched Hematopoetic Stem Cell Infusion is being developed by Tourmaline Bio, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TRML. The company is conducting clinical research on this therapy for Sickle Cell Disease, with the therapy currently in Phase 1 development.
Enriched Hematopoetic Stem Cell Infusion is in Phase 1 clinical development. It is an investigational therapy for Sickle Cell Disease and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 9 participants, and the therapy remains under investigation.
Enriched Hematopoetic Stem Cell Infusion has been studied in one clinical trial, identified as NCT00777231, titled 'Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies.' This Phase 1 trial, conducted in the United States, enrolled 9 participants with Sickle Cell Disease and has been completed.